Coherus director granted 30K RSUs and 60K options
Coherus Oncology, Inc. director Newcomer Lee Nisley reported compensation-related equity grants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Coherus Oncology, Inc. director Newcomer Lee Nisley reported compensation-related equity grants. The reporting person received 30,000 shares of Common Stock, which footnotes describe as restricted stock units (RSUs) that convert into one share of common stock per unit upon vesting. All 30,000 RSUs vest on the one-year anniversary of June 3, 2026, contingent on continued service. In addition, the reporting person was granted 60,000 stock options with an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable for all 60,000 underlying shares of Common Stock on June 3, 2027, also subject to continued service with the company.
Insider Trade Summary
Grant/Award: 90,000 shares
Grant/Award
2 txns
Insider
Newcomer Lee Nisley
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 30,000 shares (Direct)
Footnotes (2)
- F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- F2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Key Figures
RSU grant: 30,000 RSUs
RSU vesting date: June 3, 2027
Stock options granted: 60,000 options
+5 more
8 metrics
RSU grant
30,000 RSUs
Common Stock, 1 share per RSU upon vesting
RSU vesting date
June 3, 2027
One-year anniversary of June 3, 2026, subject to continued service
Stock options granted
60,000 options
Right to buy Common Stock
Option exercise price
$1.45 per share
Stock Option (Right to Buy) grant
Option expiration
June 5, 2036
Expiration date of stock options
Option vesting date
June 3, 2027
100% of underlying shares vest and become exercisable
Common shares after grant
30,000 shares
Total shares of Common Stock following RSU grant
Options after grant
60,000 options
Total stock options following this award
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 1.4500"
exercise price financial
"conversion_or_exercise_price: "1.4500" for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the RSUs shall vest on the one year anniversary of June 3, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-06-05T00:00:00.000Z" for the stock option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity did the reporting person receive in Coherus Oncology (CHRS)?
The reporting person received 30,000 RSUs and 60,000 stock options in Coherus Oncology. The RSUs convert one-for-one into common shares at vesting, while the options allow future share purchases at a $1.45 exercise price.
When do the 30,000 Coherus Oncology (CHRS) RSUs vest?
The 30,000 RSUs vest 100% on the one-year anniversary of June 3, 2026. Vesting is contingent on the reporting person maintaining a continued service relationship with Coherus Oncology through that vesting date.
What are the terms of the 60,000 Coherus Oncology (CHRS) stock options?
The grant covers 60,000 stock options with a $1.45 exercise price per share. All underlying shares vest and become exercisable on June 3, 2027, subject to the reporting person’s continued service with Coherus Oncology.
Are the Coherus Oncology (CHRS) equity awards part of routine compensation?
The filing classifies both transactions under code A, meaning a grant, award, or other acquisition. This indicates the 30,000 RSUs and 60,000 options are compensation-related awards rather than open-market purchases or sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
